{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:45:08Z","timestamp":1791895508610,"version":"4.3.4"},"reference-count":313,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Missouri Research Board and Research Council"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is growing in parallel with the obesity epidemic. No pharmacological treatment is available to treat NAFLD, specifically. The reason might be that NAFLD is a multi-factorial disease with an incomplete understanding of the mechanisms involved, an absence of accurate and inexpensive imaging tools, and lack of adequate non-invasive biomarkers. NAFLD consists of the accumulation of excess lipids in the liver, causing lipotoxicity that might progress to metabolic-associated steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma. The mechanisms for the pathogenesis of NAFLD, current interventions in the management of the disease, and the role of sirtuins as potential targets for treatment are discussed here. In addition, the current diagnostic tools, and the role of non-coding RNAs as emerging diagnostic biomarkers are summarized. The availability of non-invasive biomarkers, and accurate and inexpensive non-invasive diagnosis tools are crucial in the detection of the early signs in the progression of NAFLD. This will expedite clinical trials and the validation of the emerging therapeutic treatments.<\/jats:p>","DOI":"10.3390\/biom12060824","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:00:38Z","timestamp":1655157638000},"page":"824","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":388,"title":["NAFLD: Mechanisms, Treatments, and Biomarkers"],"prefix":"10.3390","volume":"12","author":[{"given":"Fatiha","family":"Nassir","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2013A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in Lean Individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1440-1746.2010.06443.x","article-title":"Nonalcoholic fatty liver disease across ethno-racial groups: Do Asian-American adults represent a new at-risk population?","volume":"26","author":"Tabibian","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/ijo.2017.309","article-title":"Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes","volume":"42","author":"Browning","year":"2018","journal-title":"Int. J. Obes."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41575-019-0169-z","article-title":"NAFLD in children: New genes, new diagnostic modalities and new drugs","volume":"16","author":"Nobili","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1083\/jcb.72.2.441","article-title":"Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study","volume":"72","author":"Blouin","year":"1977","journal-title":"J. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1083\/jcb.201903090","article-title":"The cell biology of the hepatocyte: A membrane trafficking machine","volume":"218","author":"Schulze","year":"2019","journal-title":"J. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hep.1840060430","article-title":"Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver","volume":"6","author":"Bouwens","year":"1986","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.7150\/ijbs.47143","article-title":"Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?","volume":"16","author":"Chen","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Khomich, O., Ivanov, A.V., and Bartosch, B. (2019). Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis. Cells, 9.","DOI":"10.3390\/cells9010024"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MOL.0000000000000535","article-title":"Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis","volume":"29","author":"Peters","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gonzalez-Paredes, F.J., Hern\u00e1ndez Mesa, G., Morales Arraez, D., Marcelino Reyes, R., Abrante, B., Diaz-Flores, F., Salido, E., Quintero, E., and Hern\u00e1ndez-Guerra, M. (2016). Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156650"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","article-title":"Nonalcoholic Fatty Liver Disease: Cytokine-Adipokine Interplay and Regulation of Insulin Resistance","volume":"131","author":"Tilg","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"key":"ref_29","first-page":"1","article-title":"Triglyceride Metabolism in the Liver","volume":"8","author":"Cohen","year":"2017","journal-title":"Compr. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MOL.0b013e3283462e16","article-title":"Hepatic fatty acid partitioning","volume":"22","author":"Hodson","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1073\/pnas.161284298","article-title":"A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver","volume":"98","author":"Yamashita","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.23094","article-title":"Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis","volume":"50","author":"Fujita","year":"2009","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1172\/JCI104648","article-title":"Sites of initial removal of chylomicron triglyceride fatty acids from the blood","volume":"41","author":"Nestel","year":"1962","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S0029665119000569","article-title":"The influence of dietary fatty acids on liver fat content and metabolism","volume":"79","author":"Hodson","year":"2020","journal-title":"Proc. Nutr. Soc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3748\/wjg.v20.i7.1746","article-title":"Modulation of hepatic steatosis by dietary fatty acids","volume":"20","author":"Ferramosca","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1042\/bst0301064","article-title":"Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase","volume":"30","author":"Hardie","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1432-1033.1978.tb20893.x","article-title":"Inhibition of rat-liver acetyl-coenzyme-A carboxylase by palmitoyl-coenzyme A. Formation of equimolar enzyme-inhibitor complex","volume":"89","author":"Ogiwara","year":"1978","journal-title":"Eur. J. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1172\/JCI63967","article-title":"Malonyl-CoA: The regulator of fatty acid synthesis and oxidation","volume":"122","author":"Foster","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41586-018-0201-4","article-title":"Structural basis for regulation of human acetyl-CoA carboxylase","volume":"558","author":"Hunkeler","year":"2018","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1172\/JCI108764","article-title":"A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis","volume":"60","author":"McGarry","year":"1977","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2020.02.012","article-title":"Tracing insights into de novo lipogenesis in liver and adipose tissues","volume":"108","author":"Wallace","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Song, Z., Xiaoli, A.M., and Yang, F. (2018). Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues. Nutrients, 10.","DOI":"10.3390\/nu10101383"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm4074","article-title":"Transcriptional regulation of hepatic lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.nutr.27.061406.093734","article-title":"Regulation of lipolysis in adipocytes","volume":"27","author":"Duncan","year":"2007","journal-title":"Annu. Rev. Nutr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1194\/jlr.M037812","article-title":"CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob\/ob mice","volume":"54","author":"Nassir","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.2337\/db07-0907","article-title":"Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity","volume":"56","author":"Koonen","year":"2007","journal-title":"Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.18632\/aging.100652","article-title":"Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease","volume":"6","author":"Sheedfar","year":"2014","journal-title":"Aging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"19034","DOI":"10.1074\/jbc.M115.640292","article-title":"Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance","volume":"290","author":"Steneberg","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Ochoa","year":"2011","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"32523","DOI":"10.1074\/jbc.M003826200","article-title":"Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice","volume":"275","author":"Coburn","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","article-title":"Gene expression in human NAFLD","volume":"294","author":"Greco","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7150\/ijms.8.599","article-title":"Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells","volume":"8","author":"Krammer","year":"2011","journal-title":"Int. J. Med. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","article-title":"Targeted deletion of FATP5 reveals multiple functions in liver metabolism: Alterations in hepatic lipid homeostasis","volume":"130","author":"Doege","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"E384","DOI":"10.1152\/ajpendo.00226.2010","article-title":"FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase","volume":"299","author":"Falcon","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00535-019-01633-2","article-title":"Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients","volume":"55","author":"Enooku","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00231381","article-title":"Fatty acid-binding protein expression in the liver: Its regulation and relationship to the zonation of fatty acid metabolism","volume":"98","author":"Bass","year":"1990","journal-title":"Mol. Cell. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/hep.22927","article-title":"Differential expression of lumican and fatty acid binding protein-1: New insights into the histologic spectrum of nonalcoholic fatty liver disease","volume":"49","author":"Charlton","year":"2009","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1152\/ajpendo.90949.2008","article-title":"Beyond triglyceride synthesis: The dynamic functional roles of MGAT and DGAT enzymes in energy metabolism","volume":"297","author":"Shi","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/biology3040801","article-title":"Glycerophosphate\/Acylglycerophosphate acyltransferases","volume":"3","author":"Yamashita","year":"2014","journal-title":"Biology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis without Increasing Inflammation or Fibrosis in Mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/science.3659919","article-title":"Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon","volume":"238","author":"Chen","year":"1987","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.nutr.20.1.169","article-title":"APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation","volume":"20","author":"Davidson","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1194\/jlr.R200014-JLR200","article-title":"Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly","volume":"44","author":"Hussain","year":"2003","journal-title":"J. Lipid Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1172\/JCI32752","article-title":"Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents","volume":"118","author":"Ota","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/cr.2016.75","article-title":"Mea6 controls VLDL transport through the coordinated regulation of COPII assembly","volume":"26","author":"Wang","year":"2016","journal-title":"Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jcmgh.2021.12.008","article-title":"Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats","volume":"13","author":"Luo","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","article-title":"Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins","volume":"291","author":"Smagris","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.31771","article-title":"Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer","volume":"74","author":"Newberry","year":"2021","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/ATVBAHA.112.301101","article-title":"A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia","volume":"33","author":"Pirruccello","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1194\/jlr.M300508-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: Roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity","volume":"45","author":"Tanoli","year":"2004","journal-title":"J. Lipid Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev.nutr.20.1.663","article-title":"The role of the microsomal triglygeride transfer protein in abetalipoproteinemia","volume":"20","author":"Aggerbeck","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","author":"Fabbrini","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semcdb.2020.04.011","article-title":"Hepatic lipid droplet homeostasis and fatty liver disease","volume":"108","author":"Seebacher","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1172\/JCI46069","article-title":"The role of lipid droplets in metabolic disease in rodents and humans","volume":"121","author":"Greenberg","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2017.03.026","article-title":"ATGL Promotes Autophagy\/Lipophagy via SIRT1 to Control Hepatic Lipid Droplet Catabolism","volume":"19","author":"Sathyanarayan","year":"2017","journal-title":"Cell Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1096\/fj.12-213454","article-title":"Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation","volume":"27","author":"Ong","year":"2013","journal-title":"FASEB J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00125-010-1895-5","article-title":"Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice","volume":"54","author":"Turpin","year":"2011","journal-title":"Diabetologia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12944-016-0194-7","article-title":"Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats","volume":"15","author":"Liu","year":"2016","journal-title":"Lipids Health Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2337\/db14-0325","article-title":"ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1\u03b1\/PPAR-\u03b1 signaling","volume":"64","author":"Khan","year":"2015","journal-title":"Diabetes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/ncb3166","article-title":"Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis","volume":"17","author":"Kaushik","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.24006","article-title":"Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning","volume":"53","author":"Ong","year":"2011","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1210\/en.2011-1518","article-title":"Fasting energy homeostasis in mice with adipose deficiency of desnutrin\/adipose triglyceride lipase","volume":"153","author":"Wang","year":"2012","journal-title":"Endocrinology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e135626","DOI":"10.1172\/jci.insight.135626","article-title":"Discordant hepatic fatty acid oxidation and triglyceride hydrolysis leads to liver disease","volume":"6","author":"Selen","year":"2021","journal-title":"JCI Insight"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nature07976","article-title":"Autophagy regulates lipid metabolism","volume":"458","author":"Singh","year":"2009","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.tem.2016.06.003","article-title":"Regulation and functions of autophagic lipolysis","volume":"27","author":"Cingolani","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrm.2017.76","article-title":"Cytosolic lipolysis and lipophagy: Two sides of the same coin","volume":"18","author":"Zechner","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2015.10.008","article-title":"Autophagy in the CNS and Periphery Coordinate Lipophagy and Lipolysis in the Brown Adipose Tissue and Liver","volume":"23","author":"Sahu","year":"2016","journal-title":"Cell Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cub.2014.02.008","article-title":"Neutral Lipid Stores and Lipase PNPLA5 Contribute to Autophagosome Biogenesis","volume":"24","author":"Dupont","year":"2014","journal-title":"Curr. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.24338","article-title":"Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis","volume":"54","author":"Wu","year":"2011","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","article-title":"The m\u00e9nage \u00e0 trois of autophagy, lipid droplets and liver disease","volume":"18","author":"Hunter","year":"2022","journal-title":"Autophagy"},{"key":"ref_102","first-page":"387626","article-title":"Mitochondrial roles and cytoprotection in chronic liver injury","volume":"2012","author":"Hamelin","year":"2012","journal-title":"Biochem. Res. Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1712","article-title":"Targeting mitochondria metabolism for cancer therapy","volume":"11","author":"Weinberg","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Leveille, M., and Estall, J.L. (2019). Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites, 9.","DOI":"10.3390\/metabo9100233"},{"key":"ref_105","first-page":"39","article-title":"Mitochondrial fatty acid synthesis, fatty acids and mitochondrial physiology","volume":"1862","author":"Kastaniotis","year":"2017","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molmed.2014.11.008","article-title":"Mitochondria: Diversity in the regulation of the NLRP3 inflammasome","volume":"21","author":"Gurung","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nature22369","article-title":"Applying systems-level spectral imaging and analysis to reveal the organelle interactome","volume":"546","author":"Valm","year":"2017","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e47928","DOI":"10.15252\/embr.201947928","article-title":"Metabolic implications of organelle-mitochondria communication","volume":"20","author":"Zorzano","year":"2019","journal-title":"EMBO Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cmet.2018.03.003","article-title":"Mitochondria Bound to Lipid Droplets Have Unique Bioenergetics, Composition, and Dynamics that Support Lipid Droplet Expansion","volume":"27","author":"Benador","year":"2018","journal-title":"Cell Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.molmet.2020.101134","article-title":"Mitochondrial oxidative function in NAFLD: Friend or foe?","volume":"50","author":"Shum","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"G193","DOI":"10.1152\/ajpgi.00426.2001","article-title":"Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis","volume":"282","author":"Pessayre","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.immuni.2012.03.005","article-title":"Dangerous Liaisons: Mitochondrial DNA Meets the NLRP3 Inflammasome","volume":"36","author":"Martinon","year":"2012","journal-title":"Immunity"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnut.2017.00042","article-title":"The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an In Vitro Model of Non-Alcoholic Fatty Liver Disease Progression","volume":"4","author":"Vecchione","year":"2017","journal-title":"Front. Nutr."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cld.2004.04.009","article-title":"Mitochondria in nonalcoholic fatty liver disease","volume":"8","author":"Caldwell","year":"2004","journal-title":"Clin. Liver Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12915-015-0201-x","article-title":"Structure and function of mitochondrial membrane protein complexes","volume":"13","year":"2015","journal-title":"BMC Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-physiol-021115-105045","article-title":"The Biochemistry and Physiology of Mitochondrial Fatty Acid \u03b2-Oxidation and Its Genetic Disorders","volume":"78","author":"Houten","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1042\/bj1340707","article-title":"The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen","volume":"134","author":"Boveris","year":"1973","journal-title":"Biochem. J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1152\/ajpendo.00492.2015","article-title":"Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity","volume":"310","author":"Patterson","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1007\/s00125-016-4084-3","article-title":"Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice","volume":"59","author":"Merry","year":"2016","journal-title":"Diabetologia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.12975","article-title":"Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives","volume":"36","author":"Salomone","year":"2016","journal-title":"Liver Int."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Larussa, T., Corea, A., Procopio, A.C., Boccuto, L., Dallio, M., Federico, A., and Luzza, F. (2021). Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. Nutrients, 13.","DOI":"10.3390\/nu13020494"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Jakubczyk, K., Skonieczna-\u017bydecka, K., Ka\u0142du\u0144ska, J., Stachowska, E., Gutowska, I., and Janda, K. (2020). Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease\u2014A Meta-Analysis. Nutrients, 12.","DOI":"10.3390\/nu12082435"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.18632\/aging.102972","article-title":"Role of mitochondrial quality control in the pathogenesis of nonalcoholic fatty liver disease","volume":"12","author":"Li","year":"2020","journal-title":"Aging"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-018-0059-z","article-title":"Mitochondrial quality control mechanisms as molecular targets in cardiac ageing","volume":"15","author":"Picca","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Cioffi, F., Giacco, A., Petito, G., de Matteis, R., Senese, R., Lombardi, A., de Lange, P., Moreno, M., Goglia, F., and Lanni, A. (2022). Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding. Genes, 13.","DOI":"10.3390\/genes13020315"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"584800","DOI":"10.3389\/fcell.2020.584800","article-title":"Mitochondrial Dynamics in Adult Cardiomyocytes and Heart Diseases","volume":"8","author":"Li","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1007\/s00018-021-03775-0","article-title":"Mitochondrial quality control: From molecule to organelle","volume":"78","author":"Tait","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_134","first-page":"190","article-title":"Role of mitochondrial depolarization and disrupted mitochondrial homeostasis in non-alcoholic steatohepatitis and fibrosis in mice","volume":"11","author":"Krishnasamy","year":"2019","journal-title":"Int. J. Physiol. Pathophysiol. Pharm."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.-F., Gautier, C.A., Shen, J., Cookson, M.R., and Youle, R.J. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol., 8.","DOI":"10.1371\/journal.pbio.1000298"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1073\/pnas.1506593112","article-title":"Defining roles of PARKIN and ubiquitin phosphorylation by PINK1 in mitochondrial quality control using a ubiquitin replacement strategy","volume":"112","author":"Ordureau","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature14893","article-title":"The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy","volume":"524","author":"Lazarou","year":"2015","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"210255","DOI":"10.1098\/rsob.210255","article-title":"Selective localization of Mfn2 near PINK1 enables its preferential ubiquitination by Parkin on mitochondria","volume":"12","author":"Vranas","year":"2022","journal-title":"Open Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/MCB.00167-12","article-title":"BNip3 regulates mitochondrial function and lipid metabolism in the liver","volume":"32","author":"Glick","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrm.2017.66","article-title":"Mitochondrial diseases: The contribution of organelle stress responses to pathology","volume":"19","author":"Suomalainen","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Moore, M.P., Cunningham, R.P., Meers, G.M., Johnson, S.A., Wheeler, A.A., Ganga, R.R., Spencer, N.M., Pitt, J.B., Diaz-Arias, A., and Swi, A.I.A. (2022). Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. Hepatology.","DOI":"10.1002\/hep.32324"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1096\/fj.08-108464","article-title":"Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats","volume":"22","author":"Perra","year":"2008","journal-title":"FASEB J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13578-016-0113-7","article-title":"Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD","volume":"6","author":"Sinha","year":"2016","journal-title":"Cell Biosci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"709828","DOI":"10.1155\/2014\/709828","article-title":"Formation and regulation of mitochondrial membranes","volume":"2014","author":"Schenkel","year":"2014","journal-title":"Int. J. Cell Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.201006159","article-title":"Making heads or tails of phospholipids in mitochondria","volume":"192","author":"Osman","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Flis, V.V., and Daum, G. (2013). Lipid transport between the endoplasmic reticulum and mitochondria. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a013235"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.mito.2009.02.005","article-title":"Mitofusin-2 regulates mitochondrial and endoplasmic reticulum morphology and tethering: The role of Ras","volume":"9","author":"Scorrano","year":"2009","journal-title":"Mitochondrion"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbrc.2017.06.097","article-title":"Mitochondria-associated membranes (MAMs): An emerging platform connecting energy and immune sensing to metabolic flexibility","volume":"500","author":"Rieusset","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3389\/fcell.2020.00595","article-title":"Mitochondria-Associated ER Membranes\u2013The Origin Site of Autophagy","volume":"8","author":"Yang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1002\/edm2.105","article-title":"Drug discovery and treatment paradigms in nonalcoholic steatohepatitis","volume":"3","author":"Noureddin","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Mantovani, A., and Dalbeni, A. (2021). Treatments for NAFLD: State of Art. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052350"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e20491","DOI":"10.2196\/20491","article-title":"Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping","volume":"23","author":"Hallsworth","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/hep.25548","article-title":"Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease","volume":"55","author":"Sullivan","year":"2012","journal-title":"Hepatology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3727\/105221617X15124844266408","article-title":"The Effects of Physical Exercise on Fatty Liver Disease","volume":"18","author":"Sud","year":"2018","journal-title":"Gene Expr."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1210\/jc.2016-2353","article-title":"Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD","volume":"101","author":"Cuthbertson","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: Facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study","volume":"155","author":"Castellanos","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","article-title":"Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review","volume":"22","author":"Golabi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tem.2019.07.013","article-title":"Are Lifestyle Therapies Effective for NAFLD Treatment?","volume":"30","author":"Kurzbach","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/oby.22964","article-title":"A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD","volume":"28","author":"Moore","year":"2020","journal-title":"Obesity"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3350\/cmh.2018.0086","article-title":"Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes","volume":"25","author":"Banitalebi","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jhepr.2021.100253","article-title":"Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD","volume":"3","author":"Oh","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.23129","article-title":"Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss","volume":"50","author":"Johnson","year":"2009","journal-title":"Hepatology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/apt.15989","article-title":"Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention","volume":"52","author":"Naimimohasses","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"G874","DOI":"10.1152\/ajpgi.00510.2010","article-title":"Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model","volume":"300","author":"Rector","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/dbi18-0043","article-title":"Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications","volume":"69","author":"Thyfault","year":"2020","journal-title":"Diabetes"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur. J. Sport Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"G619","DOI":"10.1152\/ajpgi.00428.2007","article-title":"Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats","volume":"294","author":"Rector","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes. Relat Dis"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep4.1814","article-title":"What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?","volume":"5","author":"Alkhouri","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"Jama"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Lange, N.F., Graf, V., Caussy, C., and Dufour, J.F. (2022). PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084305"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): Structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile Acids and FXR: Novel Targets for Liver Diseases","volume":"7","author":"Stofan","year":"2020","journal-title":"Front. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in steatohepatitis and fibrosis in mice","volume":"1","author":"Delgado","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Investig"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"172715","DOI":"10.1016\/j.ejphar.2019.172715","article-title":"Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy","volume":"864","author":"Yu","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: In NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.omtn.2022.04.010","article-title":"Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice","volume":"28","author":"Bartesaghi","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"154752","DOI":"10.1016\/j.metabol.2021.154752","article-title":"Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes","volume":"121","author":"Ciardullo","year":"2021","journal-title":"Metabolism"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1 in fatty liver diseases","volume":"13","author":"Ding","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"248","DOI":"10.37349\/emed.2020.00017","article-title":"Role of acetylation in nonalcoholic fatty liver disease: A focus on SIRT1 and SIRT3","volume":"1","author":"Nassir","year":"2020","journal-title":"Explor. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.3748\/wjg.v22.i46.10084","article-title":"Sirtuins and nonalcoholic fatty liver disease","volume":"22","author":"Nassir","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature08778","article-title":"SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation","volume":"464","author":"Hirschey","year":"2010","journal-title":"Nature"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/1573399812666160217122413","article-title":"Mitochondrial Post-translational Modifications and Metabolic Control: Sirtuins and Beyond","volume":"13","author":"Kulkarni","year":"2017","journal-title":"Curr. Diabetes Rev."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1152\/physrev.00022.2011","article-title":"Sirtuin 1 and sirtuin 3: Physiological modulators of metabolism","volume":"92","author":"Nogueiras","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/ars.2017.7290","article-title":"The Role of Sirtuins in Antioxidant and Redox Signaling","volume":"28","author":"Singh","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1074\/jbc.M609554200","article-title":"Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1","volume":"282","author":"Tanno","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1073\/pnas.0712145105","article-title":"A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy","volume":"105","author":"Lee","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1038\/s41598-021-87759-x","article-title":"SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways","volume":"11","author":"Majeed","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_210","first-page":"410","article-title":"Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients","volume":"44","author":"Wu","year":"2014","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.bbadis.2017.08.004","article-title":"Ablation of systemic SIRT1 activity promotes nonalcoholic fatty liver disease by affecting liver-mesenteric adipose tissue fatty acid mobilization","volume":"1863","author":"Cheng","year":"2017","journal-title":"Biochim. Et Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s12020-014-0465-x","article-title":"Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients","volume":"49","author":"Mariani","year":"2014","journal-title":"Endocrine"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1074\/jbc.M111421200","article-title":"Diminished hepatic response to fasting\/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c","volume":"277","author":"Liang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature03354","article-title":"Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1","volume":"434","author":"Rodgers","year":"2005","journal-title":"Nature"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","article-title":"Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation","volume":"9","author":"Purushotham","year":"2009","journal-title":"Cell Metab."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1474-9726.2007.00335.x","article-title":"SIRT1 transgenic mice show phenotypes resembling calorie restriction","volume":"6","author":"Bordone","year":"2007","journal-title":"Aging Cell"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7150\/ijbs.6.682","article-title":"Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition","volume":"6","author":"Wang","year":"2010","journal-title":"Int. J. Biol. Sci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1039\/C8FO02298D","article-title":"Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease","volume":"10","author":"Ren","year":"2019","journal-title":"Food Funct."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOL.0b013e328328d0a4","article-title":"PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure","volume":"20","author":"Auwerx","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Gureev, A.P., Shaforostova, E.A., and Popov, V.N. (2019). Regulation of Mitochondrial Biogenesis as a Way for Active Longevity: Interaction Between the Nrf2 and PGC-1\u03b1 Signaling Pathways. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00435"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/01.RES.0000256090.42690.05","article-title":"AMP-activated protein kinase in metabolic control and insulin signaling","volume":"100","author":"Towler","year":"2007","journal-title":"Circ. Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Feige","year":"2009","journal-title":"Nature"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"12017","DOI":"10.1073\/pnas.0705070104","article-title":"AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha","volume":"104","author":"Handschin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"de Gregorio, E., Colell, A., Morales, A., and Mar\u00ed, M. (2020). Relevance of SIRT1-NF-\u03baB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113858"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2012.04.003","article-title":"SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function","volume":"15","author":"Price","year":"2012","journal-title":"Cell Metab."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Xiong, X., Yu, J., Fan, R., Zhang, C., Xu, L., Sun, X., Huang, Y., Wang, Q., Ruan, H.B., and Qian, X. (2019). NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212523"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fonc.2020.00358","article-title":"NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation","volume":"10","author":"Audrito","year":"2020","journal-title":"Front. Oncol"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1113\/JP280908","article-title":"NAD(+) and NAFLD\u2013caution, causality and careful optimism","volume":"600","author":"Dall","year":"2022","journal-title":"J. Physiol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/dom.12171","article-title":"The importance of NAMPT\/NAD\/SIRT1 in the systemic regulation of metabolism and ageing","volume":"15","author":"Imai","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bbrc.2017.09.042","article-title":"MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1","volume":"493","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.7150\/thno.45922","article-title":"Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/pro.50","article-title":"Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3","volume":"18","author":"Jin","year":"2009","journal-title":"Protein Sci."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/jcb.22795","article-title":"Characterization of murine SIRT3 transcript variants and corresponding protein products","volume":"111","author":"Yang","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gene.2011.07.029","article-title":"Murine Sirt3 protein isoforms have variable half-lives","volume":"488","author":"Yang","year":"2011","journal-title":"Gene"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1128\/MCB.01636-07","article-title":"Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation","volume":"27","author":"Lombard","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1073\/pnas.0603968103","article-title":"Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2","volume":"103","author":"Schwer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1073\/pnas.0803790105","article-title":"A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis","volume":"105","author":"Ahn","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Kong, X., Wang, R., Xue, Y., Liu, X., Zhang, H., Chen, Y., Fang, F., and Chang, Y. (2010). Sirtuin 3, a new target of PGC-1\u03b1, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011707"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1194\/jlr.M080952","article-title":"Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice","volume":"59","author":"Nassir","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jcb.22531","article-title":"Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms","volume":"110","author":"Bao","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.molcel.2011.07.019","article-title":"SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome","volume":"44","author":"Hirschey","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/BJ20100791","article-title":"Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation","volume":"433","author":"Kendrick","year":"2011","journal-title":"Biochem. J."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.freeradbiomed.2010.07.009","article-title":"SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity","volume":"49","author":"Bao","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12964-020-00640-8","article-title":"SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1\u03b1-LIPIN 1 pathway and increasing CD36 through Nrf2","volume":"18","author":"Barroso","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.redox.2018.07.011","article-title":"Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy","volume":"18","author":"Li","year":"2018","journal-title":"Redox Biol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41418-019-0356-z","article-title":"SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity","volume":"27","author":"Zhang","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"He, J., Hu, B., Shi, X., Weidert, E., Lu, P., Xu, M., Huang, M., Kelley, E., and Xie, W. (2013). Activation of the Aryl Hydrocarbon Receptor Sensitizes Mice to Nonalcoholic Steatohepatitis by Deactivating Mitochondrial Sirtuin Deacetylase Sirt3. Mol. Cell. Biol., 33.","DOI":"10.1128\/MCB.01658-12"},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Martinou, E., Pericleous, M., Stefanova, I., Kaur, V., and Angelidi, A.M. (2022). Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020407"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2018.03.004","article-title":"Sirtuin activators and inhibitors: Promises, achievements, and challenges","volume":"188","author":"Dai","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"752117","DOI":"10.3389\/fphys.2021.752117","article-title":"Human Sirtuin Regulators: The \"Success\" Stories","volume":"12","author":"Curry","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000090320","article-title":"Emerging therapies for liver fibrosis","volume":"24","author":"Fowell","year":"2006","journal-title":"Dig. Dis."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/hep.28699","article-title":"Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"64","author":"Hannah","year":"2016","journal-title":"Hepatology"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0168-8278(01)00094-0","article-title":"Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology","volume":"35","author":"Skelly","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Poynard, T., Lassailly, G., Diaz, E., Clement, K., Ca\u00efazzo, R., Tordjman, J., Munteanu, M., Perazzo, H., Demol, B., and Callafe, R. (2012). Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: Meta analysis of individual patient data. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030325"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41598-021-04361-x","article-title":"Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease","volume":"12","author":"Unsal","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Graupera, I., Thiele, M., Serra-Burriel, M., Caballeria, L., Roulot, D., Wong, G.L.-H., Fabrellas, N., Guha, I.N., Arslanow, A., and Exp\u00f3sito, C. (2021). Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/S0168-8278(20)31314-3"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/liv.13054","article-title":"Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease","volume":"36","author":"Siddiqui","year":"2016","journal-title":"Liver Int."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40618-020-01188-7","article-title":"Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD","volume":"43","author":"Ciardullo","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_267","first-page":"9026","article-title":"Role of liver biopsy in nonalcoholic fatty liver disease","volume":"20","author":"Nalbantoglu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(86)90883-4","article-title":"Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver","volume":"1","author":"Maharaj","year":"1986","journal-title":"Lancet"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000071293","article-title":"Bleeding complications after percutaneous liver biopsy","volume":"67","author":"Terjung","year":"2003","journal-title":"Digestion"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Schmitz, S.M., Kroh, A., Ulmer, T.F., Andruszkow, J., Luedde, T., Brozat, J.F., Neumann, U.P., and Alizai, P.H. (2020). Evaluation of NAFLD and fibrosis in obese patients\u2013a comparison of histological and clinical scoring systems. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01400-1"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2013.07.042","article-title":"Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"Cusi","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: Non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"634409","DOI":"10.3389\/fimmu.2020.634409","article-title":"Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease","volume":"11","author":"Lambrecht","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4291\/wjgp.v8.i2.11","article-title":"Nonalcoholic fatty liver disease: Diagnostic biomarkers","volume":"8","author":"Hadizadeh","year":"2017","journal-title":"World J. Gastrointest. PathoPhysiol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","volume":"50","author":"Ajmera","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"e00081","DOI":"10.14309\/ctg.0000000000000081","article-title":"Detection of Liver Steatosis With a Novel Ultrasound-Based Technique: A Pilot Study Using MRI-Derived Proton Density Fat Fraction as the Gold Standard","volume":"10","author":"Ferraioli","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1148\/radiol.2511080666","article-title":"Nonalcoholic fatty liver disease: Diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T","volume":"251","author":"Yokoo","year":"2009","journal-title":"Radiology"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/jmri.24284","article-title":"Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects","volume":"39","author":"Negrete","year":"2014","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Ali, A.H., Al Juboori, A., Petroski, G.F., Diaz-Arias, A.A., Syed-Abdul, M.M., Wheeler, A.A., Ganga, R.R., Pitt, J.B., Spencer, N.M., and Hammoud, G.M. (2022). The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051201"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/HMER.S245455","article-title":"Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch","volume":"12","author":"Serra","year":"2020","journal-title":"Hepat. Med."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/hmg\/ddl046","article-title":"Non-coding RNA","volume":"15","author":"Mattick","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"194417","DOI":"10.1016\/j.bbagrm.2019.194417","article-title":"Non-coding RNA regulatory networks","volume":"1863","author":"Panni","year":"2020","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"8822859","DOI":"10.1155\/2020\/8822859","article-title":"Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers","volume":"2020","author":"Khalifa","year":"2020","journal-title":"Dis. Markers"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"15079","DOI":"10.3748\/wjg.v20.i41.15079","article-title":"MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease","volume":"20","author":"Panera","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.7150\/ijbs.59588","article-title":"MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"17","author":"Fang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1080\/21655979.2022.2051815","article-title":"MM-associated circular RNA downregulates microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells","volume":"13","author":"Qian","year":"2022","journal-title":"Bioengineered"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/liv.13097","article-title":"Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease","volume":"36","author":"Molina","year":"2016","journal-title":"Liver Int."},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Akuta, N., Kawamura, Y., Suzuki, F., Saitoh, S., Arase, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., and Suzuki, Y. (2016). Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0557-6"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/cbdd.12398","article-title":"Up regulation of liver-enriched transcription factors HNF4a and HNF6 and liver-specific microRNA (miR-122) by inhibition of let-7b in mesenchymal stem cells","volume":"85","author":"Alizadeh","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/2211536607666180531093302","article-title":"Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"7","author":"Jampoka","year":"2018","journal-title":"Microrna"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.3390\/ijms14048437","article-title":"Dual role of microRNAs in NAFLD","volume":"14","author":"Ceccarelli","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol. Med."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ijpo.12261","article-title":"Circulating levels of miR-122 and nonalcoholic fatty liver disease in pre-pubertal obese children","volume":"13","author":"Brandt","year":"2018","journal-title":"Pediatr. Obes."},{"key":"ref_299","doi-asserted-by":"crossref","unstructured":"Sendi, H., Mead, I., Wan, M., Mehrab-Mohseni, M., Koch, K., Atala, A., Bonkovsky, H.L., and Bishop, C.E. (2018). miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200847"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1038\/srep13729","article-title":"Effect of miR-34a in regulating steatosis by targeting PPAR\u03b1 expression in nonalcoholic fatty liver disease","volume":"5","author":"Ding","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jhep.2018.08.026","article-title":"MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-\u03baB-TNF\u03b1 pathway","volume":"70","author":"Zhang","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbrc.2016.04.065","article-title":"MicroRNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3","volume":"474","author":"Cheng","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cell.2020.08.009","article-title":"Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output","volume":"183","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"ref_304","first-page":"29","article-title":"Role of LncRNA-activated by transforming growth factor beta in the progression of hepatitis C virus-related liver fibrosis","volume":"22","author":"Fu","year":"2016","journal-title":"Discov. Med."},{"key":"ref_305","doi-asserted-by":"crossref","unstructured":"Ding, L.-J., Li, Y., Wang, S.-D., Wang, X.-S., Fang, F., Wang, W.-Y., Lv, P., Zhao, D.-H., Wei, F., and Qi, L. (2016). Long noncoding RNA lncCAMTA1 promotes proliferation and cancer stem cell-like properties of liver cancer by inhibiting CAMTA1. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101617"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"645647","DOI":"10.3389\/fcell.2021.645647","article-title":"Biological Function of Long Non-coding RNA (LncRNA) Xist","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_307","first-page":"299","article-title":"Genome-wide identification of long noncoding RNAs in CCl4-induced liver fibrosis via RNA sequencing","volume":"18","author":"Gong","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Hanson, A., Wilhelmsen, D., and DiStefano, J.K. (2018). The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA, 4.","DOI":"10.3390\/ncrna4030018"},{"key":"ref_309","doi-asserted-by":"crossref","unstructured":"Atanasovska, B., Rensen, S.S., Marsman, G., Shiri-Sverdlov, R., Withoff, S., Kuipers, F., Wijmenga, C., van de Sluis, B., and Fu, J. (2021). Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis. Cells, 10.","DOI":"10.3390\/cells10081883"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"18558","DOI":"10.1074\/jbc.C500089200","article-title":"Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D","volume":"280","author":"Basso","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3233\/JAD-160822","article-title":"Cyclophilin D promotes brain mitochondrial F1FO ATP synthase dysfunction in aging mice","volume":"55","author":"Gauba","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.redox.2018.01.004","article-title":"Blocking mitochondrial cyclophilin D ameliorates TSH-impaired defensive barrier of artery","volume":"15","author":"Liu","year":"2018","journal-title":"Redox Biol."},{"key":"ref_313","first-page":"1249630","article-title":"Thyroid Stimulating Hormone Triggers Hepatic Mitochondrial Stress through Cyclophilin D Acetylation","volume":"2020","author":"Wang","year":"2020","journal-title":"Oxid. Med. Cell. Longev."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/6\/824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:48Z","timestamp":1760138928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/6\/824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":313,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["biom12060824"],"URL":"https:\/\/doi.org\/10.3390\/biom12060824","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}